CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) block immune checkpoint proteins such as programmed death protein-1 (PD-1) and its ligand, programmed death ligand-1 (PD-L1), thereby preventing the innate cytotoxic T-cell response against non-small cell lung cancer (NSCLC) cells 1.